Despite these limitations, some drugs have made it into the clinic including several anticonvulsants like gabapentin and pregabalin for neuropathic pain, albeit with limited efficiency, and antagonists or antibodies against calcitonin gene–related peptides (CGRP) for migraine.29 To date, 2 different classes targeting CGRP have been developed for migraine therapy: There are small molecule receptor antagonists of the CGRP receptor and blocking monoclonal antibodies. The gene discussed is CALCA; the disease is migraine disorder.